Pharmaceuticals News and Research

RSS

Research roundup: Lowering health costs of the poorest sick; Local variations in health spending

Olmstead County, Minn., which earlier required just restaurants to be smoke-free, enacted a law in 2007 that banned smoking in all workplaces. Researchers reported "a substantial decline in the incidence of MI from 18 months before the smoke-free restaurant law was implemented to 18 months after the comprehensive smoke-free workplace law was implemented 5 years later.

3 Nov 2012

Top-line results from Aerie Pharmaceuticals' AR-13324 Phase 2a study on glaucoma

Aerie Pharmaceuticals, a biotechnology company focused on the discovery and development of novel treatments for glaucoma, today announced positive top-line results from its Phase 2a study evaluating AR-13324 for the treatment of glaucoma.

3 Nov 2012

FDA expands Janssen’s Xarelto use to reduce risk of DVT and PE

The U.S. Food and Drug Administration today expanded the approved use of Xarelto (rivaroxaban) to include treating deep vein thrombosis (DVT) or pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE following initial treatment.

3 Nov 2012

Physicists to bring to market new drug-discovery tool using genetic sequencing

Today physicists at Wake Forest University and NanoMedica, their biotechnology company partner, received a $700,000 grant from the National Institutes of Health to bring to market a new drug-discovery tool using next-generation genetic sequencing.

3 Nov 2012

Takeda, Affymax announce data from OMONTYS Phase 3 studies on anemia due to CKD

Affymax, Inc. and Takeda Pharmaceuticals U.S.A., Inc. (TPUSA) today announced the presentation of post-hoc sub-group analyses of the EMERALD Phase 3 studies that evaluated OMONTYS (peginesatide) Injection, an erythropoiesis-stimulating agent (ESA), for the treatment of anemia due to chronic kidney disease (CKD) in adult dialysis patients.

2 Nov 2012

Janssen, Vertex to evaluate TMC435 and VX-135 in Phase 2 HCV study

Janssen Pharmaceuticals, Inc. today announced that it has entered into a non-exclusive collaboration with Vertex Pharmaceuticals Incorporated to evaluate in a Phase 2 study the safety and efficacy of an all-oral regimen for the treatment of hepatitis C (HCV).

2 Nov 2012

Inotek announces final data from trabodenoson Phase 2 trial on PAOG or ocular hypertension

Inotek Pharmaceuticals Corp., a leader in the development of innovative drug candidates to address significant diseases of the eye, today announced that final data from a Phase 2 clinical trial of trabodenoson, also known as INO-8875, in patients with primary open-angle glaucoma or ocular hypertension will be presented at the Ophthalmology Innovation Summit on Thursday, November 8, 2012 at the Chicago Marriott Downtown Magnificent Mile in Chicago, IL.

2 Nov 2012

Teva third quarter 2012 net revenues increase 14% to $5.0 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended September 30, 2012.

1 Nov 2012

Transformatix Technologies, NCH partner to create BioLinQ

The latest significant biomedical informatics technology is not coming from the biotech industry or a university. In fact, it's coming from a children's hospital.

1 Nov 2012

Proposing standards and guidelines for Rett syndrome research

There is an urgent need for new drugs to treat Rett syndrome, a rare and severe neurological disease mainly affecting girls. A bottleneck in drug development for this syndrome is a lack of clarity at the level of preclinical research. Key researchers in this field now tackle this issue, proposing standards and guidelines for Rett syndrome research, in an Open Access review article published on Oct. 31, 2012 in Disease Models & Mechanisms (DMM).

1 Nov 2012

Novartis resumes distribution of two seasonal influenza vaccines in Canada

Novartis Pharmaceuticals Canada Inc. has announced it is resuming distribution of two seasonal influenza vaccines in Canada, Fluad and Agriflu, following the announcement by Health Canada earlier today that it has completed its review of safety information for Agriflu and Fluad and is releasing the two vaccines for immediate use.

1 Nov 2012

Isis announces preliminary data from ISIS-STAT3 Phase 1 study on cancer

Isis Pharmaceuticals, Inc. announced that preliminary data from the Phase 1 study of ISIS-STAT3Rx in patients with cancer were presented today at the Oligonucleotide Therapeutics Society in Boston.

1 Nov 2012

Additional data from EnVivo’s EVP-6124 Phase 2b trial on AD presented at CTAD meeting

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, today presented pharmacokinetic and pharmacodynamic data along with the previously reported statistically significant clinical results from its Phase 2b clinical trial of EVP-6124, a novel alpha-7 agonist, in patients with Alzheimer's disease.

1 Nov 2012

AKP America commences ART-123 Phase 3 trial in severe sepsis patients with coagulopathy

Asahi Kasei Pharma America Corp. today announced the initiation of an 800-patient Phase 3 clinical trial for ART-123 (recombinant human thrombomodulin, marketed as Recomodulin in Japan) in severe sepsis patients with coagulopathy.

1 Nov 2012

Watson acquires Actavis

Watson Pharmaceuticals, Inc. today announced that it has completed the acquisition of the Actavis Group for EUR 4.25 billion.

1 Nov 2012

Integra Holdings, a biopharmaceutical holding company, announced by Yissum

Yissum Research and Development Company of the Hebrew University of Jerusalem, the technology transfer company of the Hebrew University, announced today the inception of its subsidiary, Integra Holdings, a holding company focusing on biopharmaceutical companies based on inventions of researchers from the Hebrew University.

31 Oct 2012